Hank Mansbach

Hank Mansbach

Company: 89Bio

Job title: Chief Medical Officer


Dr. Hank Mansbach is chief medical officer of 89bio. Dr. Mansbach has more than 20 years of clinical, regulatory, and medical affairs experience working across all stages of product development in a wide range of disease states. Most recently, Dr. Mansbach was head of metabolic and neurology global clinical development at Ultragenyx. There, he led clinical development for several programs on rare inborn errors of metabolism. Before Ultragenyx, Dr. Mansbach served as VP of medical affairs at Medivation, where he played a key role in the development and commercialization of enzalutamide for the treatment of advanced prostate cancer. Earlier in his career, Dr. Mansbach served as SVP of global drug development at Valeant Pharmaceuticals and chief medical officer at Cortex Pharmaceuticals. Dr. Mansbach began his industry career at Glaxo Wellcome after clinical practice and research in neurology. He earned a medical degree from Duke University and a bachelor’s degree from Yale University.

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.